OBJECTIVE To explore the treatment efficacy of Pseudomonas aeruginosa infection by extend the administration time of piperacillin tazobactam. METHODS 167 hospitalized patients with Pseudomonas aeruginosa infection diagnosed by etiological diagnosis from Nov. 2007-Nov. 2010, and these patients showed drug resistance of piperacillin tazobactam. Before treatment, all the patients were randomly divided into two groups. Time extension group showed sensitive to piperacillin tazobactam and they were treated with 4.5 piperacillin tazobactamg, intravenous infusion for q6h. Each infusion pump was within 45min; Patients with Piperacillin tazobactam against Pseudomonas aeruginosa infection were treated by 4.5 g piperacillin tazobactam, intravenous infusion for q6h, and each infusion pump was within 45min. They were injected with 1.7mg / kg tobramycin, and intravenous drip for q6d. Conventional treatment group patients were sensitive to piperacillin tazobactam on 4.5 g piperacillin tazobactam and q6h intravenous infusion; Piperacillin tazobactam against Pseudomonas aeruginosa infection was treated by 4.5 g piperacillin tazobactam, q6h, intravenous drip and 1.7mg / kg tobramycin was used to them at the same time, and qd intravenous drip. The other treatments were the same. RESULTS The time extension could improve the efficiency than the conventional treatment group, and the incidence of adverse reactions did not show significant difference. CONCLUSION During the same dosage treatment, the extension of administration time can piperacillin tazobactam in the fT﹥ MIC meet or exceed the dosing interval of 40% -50%, and achieve good results.